No Cover Image

Journal article 752 views

Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.

Nicholas Danchin, Maddalena Lettina, Uwe Zeymer, Petr Widimsky, Alfredo Bardaji, Jose Barrabes, Angel Cequier, Marc Claeys, Leonardo De Luca, Jakob Dörler, David Erlinge, Paul Erne, Patrick Goldstein, Sasha Koul, Gilles Lemesle, Thomas Lüscher, Christian Matter, Gilles Montalescot, Dragana Radovanovic, Jose Lopez Sendón, Petr Tousek, Franz Weidinger, Clive Weston Orcid Logo, Azfar Zaman, Pontus Andell, Jin Li, Wouter Jukema

European Heart Journal - Cardiovascular Pharmacotherapy

Swansea University Author: Clive Weston Orcid Logo

Full text not available from this repository: check for access using links below.

DOI (Published version): 10.1093/ehjcvp/pvw003

Abstract

Aims To describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also prov...

Full description

Published in: European Heart Journal - Cardiovascular Pharmacotherapy
Published: 2016
URI: https://cronfa.swan.ac.uk/Record/cronfa26696
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2016-03-06T01:58:11Z
last_indexed 2019-08-15T20:17:30Z
id cronfa26696
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2019-08-15T17:52:52.1633423</datestamp><bib-version>v2</bib-version><id>26696</id><entry>2016-03-05</entry><title>Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.</title><swanseaauthors><author><sid>df85e4e0e139d0f46eb683174eba98a9</sid><ORCID>0000-0002-8995-8199</ORCID><firstname>Clive</firstname><surname>Weston</surname><name>Clive Weston</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2016-03-05</date><deptcode>PMSC</deptcode><abstract>Aims To describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registries were heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09&#x2013;3.55% in-hospital (8 registries), 0.09&#x2013;1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry).</abstract><type>Journal Article</type><journal>European Heart Journal - Cardiovascular Pharmacotherapy</journal><publisher/><keywords>Effectiveness; Safety; Acute coronary syndromes; ST-segment elevation myocardial infarction</keywords><publishedDay>27</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2016</publishedYear><publishedDate>2016-01-27</publishedDate><doi>10.1093/ehjcvp/pvw003</doi><url/><notes/><college>COLLEGE NANME</college><department>Medicine</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PMSC</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2019-08-15T17:52:52.1633423</lastEdited><Created>2016-03-05T12:43:08.0344461</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Nicholas</firstname><surname>Danchin</surname><order>1</order></author><author><firstname>Maddalena</firstname><surname>Lettina</surname><order>2</order></author><author><firstname>Uwe</firstname><surname>Zeymer</surname><order>3</order></author><author><firstname>Petr</firstname><surname>Widimsky</surname><order>4</order></author><author><firstname>Alfredo</firstname><surname>Bardaji</surname><order>5</order></author><author><firstname>Jose</firstname><surname>Barrabes</surname><order>6</order></author><author><firstname>Angel</firstname><surname>Cequier</surname><order>7</order></author><author><firstname>Marc</firstname><surname>Claeys</surname><order>8</order></author><author><firstname>Leonardo</firstname><surname>De Luca</surname><order>9</order></author><author><firstname>Jakob</firstname><surname>D&#xF6;rler</surname><order>10</order></author><author><firstname>David</firstname><surname>Erlinge</surname><order>11</order></author><author><firstname>Paul</firstname><surname>Erne</surname><order>12</order></author><author><firstname>Patrick</firstname><surname>Goldstein</surname><order>13</order></author><author><firstname>Sasha</firstname><surname>Koul</surname><order>14</order></author><author><firstname>Gilles</firstname><surname>Lemesle</surname><order>15</order></author><author><firstname>Thomas</firstname><surname>L&#xFC;scher</surname><order>16</order></author><author><firstname>Christian</firstname><surname>Matter</surname><order>17</order></author><author><firstname>Gilles</firstname><surname>Montalescot</surname><order>18</order></author><author><firstname>Dragana</firstname><surname>Radovanovic</surname><order>19</order></author><author><firstname>Jose</firstname><surname>Lopez Send&#xF3;n</surname><order>20</order></author><author><firstname>Petr</firstname><surname>Tousek</surname><order>21</order></author><author><firstname>Franz</firstname><surname>Weidinger</surname><order>22</order></author><author><firstname>Clive</firstname><surname>Weston</surname><orcid>0000-0002-8995-8199</orcid><order>23</order></author><author><firstname>Azfar</firstname><surname>Zaman</surname><order>24</order></author><author><firstname>Pontus</firstname><surname>Andell</surname><order>25</order></author><author><firstname>Jin</firstname><surname>Li</surname><order>26</order></author><author><firstname>Wouter</firstname><surname>Jukema</surname><order>27</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2019-08-15T17:52:52.1633423 v2 26696 2016-03-05 Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries. df85e4e0e139d0f46eb683174eba98a9 0000-0002-8995-8199 Clive Weston Clive Weston true false 2016-03-05 PMSC Aims To describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registries were heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09–3.55% in-hospital (8 registries), 0.09–1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry). Journal Article European Heart Journal - Cardiovascular Pharmacotherapy Effectiveness; Safety; Acute coronary syndromes; ST-segment elevation myocardial infarction 27 1 2016 2016-01-27 10.1093/ehjcvp/pvw003 COLLEGE NANME Medicine COLLEGE CODE PMSC Swansea University 2019-08-15T17:52:52.1633423 2016-03-05T12:43:08.0344461 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Nicholas Danchin 1 Maddalena Lettina 2 Uwe Zeymer 3 Petr Widimsky 4 Alfredo Bardaji 5 Jose Barrabes 6 Angel Cequier 7 Marc Claeys 8 Leonardo De Luca 9 Jakob Dörler 10 David Erlinge 11 Paul Erne 12 Patrick Goldstein 13 Sasha Koul 14 Gilles Lemesle 15 Thomas Lüscher 16 Christian Matter 17 Gilles Montalescot 18 Dragana Radovanovic 19 Jose Lopez Sendón 20 Petr Tousek 21 Franz Weidinger 22 Clive Weston 0000-0002-8995-8199 23 Azfar Zaman 24 Pontus Andell 25 Jin Li 26 Wouter Jukema 27
title Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
spellingShingle Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
Clive Weston
title_short Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
title_full Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
title_fullStr Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
title_full_unstemmed Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
title_sort Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
author_id_str_mv df85e4e0e139d0f46eb683174eba98a9
author_id_fullname_str_mv df85e4e0e139d0f46eb683174eba98a9_***_Clive Weston
author Clive Weston
author2 Nicholas Danchin
Maddalena Lettina
Uwe Zeymer
Petr Widimsky
Alfredo Bardaji
Jose Barrabes
Angel Cequier
Marc Claeys
Leonardo De Luca
Jakob Dörler
David Erlinge
Paul Erne
Patrick Goldstein
Sasha Koul
Gilles Lemesle
Thomas Lüscher
Christian Matter
Gilles Montalescot
Dragana Radovanovic
Jose Lopez Sendón
Petr Tousek
Franz Weidinger
Clive Weston
Azfar Zaman
Pontus Andell
Jin Li
Wouter Jukema
format Journal article
container_title European Heart Journal - Cardiovascular Pharmacotherapy
publishDate 2016
institution Swansea University
doi_str_mv 10.1093/ehjcvp/pvw003
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description Aims To describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registries were heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09–3.55% in-hospital (8 registries), 0.09–1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry).
published_date 2016-01-27T03:32:06Z
_version_ 1763751312128737280
score 11.012678

Similar Items